United-Guardian Q1 sales rise 16% to $2.87M; EPS $0.18 vs $0.12 YoY

UNITED GUARDIAN INC

Net income $818,902 ($0.18 per share) vs $560,895 ($0.12) in Q1 2025.
Pharmaceutical sales up 24% on Renacidin demand; cosmetic ingredient sales up 21%.
Settlement income from contract manufacturer for Renacidin shutdown in 2023 boosted results.
President sees momentum from ASI resuming regular purchases and new distribution agreements.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

UNITED GUARDIAN INC reported the first quarter of 2026 results: revenue $2,872,222, net income $818,902, EPS $0.18 per share.

Period: the first quarter of 2026
Revenue: $2,872,222
Net income: $818,902
EPS: $0.18 per share
Result: reported results

Exact text from the filing

announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

UNITED GUARDIAN INC filing history →

Source: SEC EDGAR

accession 0001171843-26-003193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.